Details of the Drug Combination

General Information of Drug Combination (ID: DCUBPZK)

Drug Combination Name
MK-1775 Carboplatin
Indication
Disease Entry Status REF
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation Phase 2 [1]
Component Drugs MK-1775   DM3WDZ5 Carboplatin   DMG281S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [6]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [6]
------------------------------------------------------------------------------------
Indication(s) of Carboplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [4]
Carcinoma 2A00-2F9Z Approved [4]
Cholangiocarcinoma 2C12.10 Approved [4]
Cutaneous melanoma 2C30 Approved [4]
Epithelial ovarian cancer 2B5D Approved [4]
Fallopian tube neoplasm N.A. Approved [4]
Gastroesophageal junction adenocarcinoma 2B71 Approved [4]
Lung adenocarcinoma N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
Non-small-cell lung cancer 2C25.Y Approved [4]
Ovarian cancer 2C73 Approved [5]
Ovarian disorder N.A. Approved [4]
Ovarian neoplasm N.A. Approved [4]
Ovarian serous cystadenocarcinoma N.A. Approved [4]
Small-cell lung cancer 2C25.Y Approved [4]
Lung large cell carcinoma N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Carboplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [8]
------------------------------------------------------------------------------------
Carboplatin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Carboplatin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [10]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [10]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [10]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [10]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [10]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [10]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Pediatric Cancer DCCRI37 N. A. Phase 1 [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02272790) Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Carboplatin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
6 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
7 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
8 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
9 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
10 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
11 ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors